Capstone expects positive adjusted EBITDA in Q2 2026
CAPS•Inventory conversion and margin expansion
- Converted $700,000 of surplus inventory into full-margin sales within six months of the Canadian Stone Industries deal.
- Integration platform redeployed inventory to higher-demand markets, supporting working-capital efficiency and margin expansion.
Positive adjusted EBITDA expected in Q2 2026
Capstone Therapeutics forecast positive Adjusted EBITDA for Q2 2026 following integration gains from recent acquisitions.
Distribution consolidation and working-capital savings
Midwest distribution network consolidation in May targeted $500,000 in annualized cost savings, unlocking $700,000 of working capital.
